ADICET BIO INC (ACET) Fundamental Analysis & Valuation
NASDAQ:ACET • US0070022076
Current stock price
8.2 USD
+0.65 (+8.61%)
At close:
8.04 USD
-0.16 (-1.95%)
After Hours:
This ACET fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ACET Profitability Analysis
1.1 Basic Checks
- In the past year ACET has reported negative net income.
- ACET had a negative operating cash flow in the past year.
- ACET had negative earnings in each of the past 5 years.
- In the past 5 years ACET always reported negative operating cash flow.
1.2 Ratios
- ACET's Return On Assets of -60.72% is on the low side compared to the rest of the industry. ACET is outperformed by 60.39% of its industry peers.
- ACET's Return On Equity of -73.36% is in line compared to the rest of the industry. ACET outperforms 51.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.72% | ||
| ROE | -73.36% | ||
| ROIC | N/A |
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ACET does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ACET Health Analysis
2.1 Basic Checks
- The number of shares outstanding for ACET has been increased compared to 1 year ago.
- Compared to 5 years ago, ACET has more shares outstanding
- ACET has a worse debt/assets ratio than last year.
2.2 Solvency
- ACET has an Altman-Z score of -4.39. This is a bad value and indicates that ACET is not financially healthy and even has some risk of bankruptcy.
- ACET's Altman-Z score of -4.39 is on the low side compared to the rest of the industry. ACET is outperformed by 60.97% of its industry peers.
- A Debt/Equity ratio of 0.00 indicates that ACET is not too dependend on debt financing.
- ACET has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ACET outperforms 47.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.39 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ACET has a Current Ratio of 7.47. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
- ACET has a Current ratio of 7.47. This is in the better half of the industry: ACET outperforms 68.93% of its industry peers.
- A Quick Ratio of 7.47 indicates that ACET has no problem at all paying its short term obligations.
- ACET's Quick ratio of 7.47 is fine compared to the rest of the industry. ACET outperforms 69.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.47 | ||
| Quick Ratio | 7.47 |
3. ACET Growth Analysis
3.1 Past
- ACET shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.14%, which is quite good.
EPS 1Y (TTM)16.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 22.74% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.99%
EPS Next 2Y19.86%
EPS Next 3Y12.91%
EPS Next 5Y22.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ACET Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ACET's earnings are expected to grow with 12.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.86%
EPS Next 3Y12.91%
5. ACET Dividend Analysis
5.1 Amount
- ACET does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ACET Fundamentals: All Metrics, Ratios and Statistics
8.2
+0.65 (+8.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-12 2026-03-12/amc
Earnings (Next)05-04 2026-05-04
Inst Owners58.98%
Inst Owner Change-0.04%
Ins Owners0.19%
Ins Owner Change-0.33%
Market Cap78.72M
Revenue(TTM)N/A
Net Income(TTM)-116.80M
Analysts86.15
Price Target54.06 (559.27%)
Short Float %6.9%
Short Ratio4.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.5%
Min EPS beat(2)-2.87%
Max EPS beat(2)1.86%
EPS beat(4)2
Avg EPS beat(4)-0.55%
Min EPS beat(4)-9.54%
Max EPS beat(4)8.37%
EPS beat(8)6
Avg EPS beat(8)4.48%
EPS beat(12)7
Avg EPS beat(12)-2.2%
EPS beat(16)9
Avg EPS beat(16)-2.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.82%
PT rev (3m)-46.79%
EPS NQ rev (1m)-2.03%
EPS NQ rev (3m)-8.66%
EPS NY rev (1m)0%
EPS NY rev (3m)7.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.49 | ||
| P/tB | 0.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-17.98
EYN/A
EPS(NY)-10.43
Fwd EYN/A
FCF(TTM)-9.74
FCFYN/A
OCF(TTM)-9.62
OCFYN/A
SpS0
BVpS16.58
TBVpS16.58
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.72% | ||
| ROE | -73.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 17.29% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.47 | ||
| Quick Ratio | 7.47 | ||
| Altman-Z | -4.39 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)246.96%
Cap/Depr(5y)333.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.58%
EPS Next Y41.99%
EPS Next 2Y19.86%
EPS Next 3Y12.91%
EPS Next 5Y22.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.43%
OCF growth 3YN/A
OCF growth 5YN/A
ADICET BIO INC / ACET Fundamental Analysis FAQ
What is the fundamental rating for ACET stock?
ChartMill assigns a fundamental rating of 1 / 10 to ACET.
Can you provide the valuation status for ADICET BIO INC?
ChartMill assigns a valuation rating of 0 / 10 to ADICET BIO INC (ACET). This can be considered as Overvalued.
What is the profitability of ACET stock?
ADICET BIO INC (ACET) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for ACET stock?
The Earnings per Share (EPS) of ADICET BIO INC (ACET) is expected to grow by 41.99% in the next year.